INAB 8-K
In8bio, Inc. (INAB)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On August 6, 2026, IN8bio, Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
d) Exhibits.
Exhibit No. |
|
Description |
99.1 |
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
IN8bio, Inc. |
|
|
|
|
|
Date: |
August 6, 2026 |
By: |
/s/ Patrick McCall |
|
|
|
Patrick McCall |
|
|
|
Chief Financial Officer and Secretary (Principal Financial and Accounting Officer) |
Exhibit 99.1
IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights
NEW YORK, August 6, 2026 - IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and γδ T cell engagers (TCEs) for cancer and autoimmune diseases, today reported financial results and business highlights for the second quarter ended June 30, 2026.
“The second quarter marked an important period of scientific and clinical validation for γδ T cell therapeutics and IN8bio. Our γδ TCE platform is progressing, with INB-619 advancing into initial animal models. We are pleased to remain on track for reporting initial in vivo data this year,” said William Ho, Chief Executive Officer and co-founder of IN8bio. “In addition, peer-reviewed and updated clinical data from our glioblastoma program continue to demonstrate a favorable safety profile and provide strong evidence that γδ T cells are clinically active and can be delivered safely to potentially improve patient outcomes. We remain focused on disciplined execution, as we continue to seek a regulatory pathway for our glioblastoma program, with the ultimate goal of bringing much needed treatment to patients.”
Advancing Next-Generation γδ TCE Platform (INB-619)
Reported Clinical and Translational Advances for DeltEx™ DRI in Newly Diagnosed Glioblastoma
During the second quarter, IN8bio reported multiple clinical and scientific milestones supporting the clinical activity of γδ T cells and IN8bio’s DeltEx™ DRI platform:
Upcoming Anticipated Milestones
Second Quarter 2026 Financial Highlights
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s pipeline is anchored by INB-600, a novel γδ T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also advancing INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical
stem cell transplantation, and INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed glioblastoma (GBM). For more information about IN8bio, visit www.IN8bio.com.
Forward Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential of IN8bio’s product candidates; the potential of IN8bio’s INB-600 platform to improve durability and safety compared with traditional CD3-targeting engagers; IN8bio’s ability to achieve anticipated milestones, including receipt of guidance from the FDA on regulatory pathways for the DeltEx™ DRI GBM program, expected presentations and data readouts from its preclinical studies and clinical trials including preclinical in vivo data for INB-619, patient dosing timelines and advancement of clinical development plans; and other statements that are not historical fact. IN8bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as IN8bio’s ability to meet anticipated deadlines and milestones; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of IN8bio’s product candidates; the risk that IN8bio may be unable to raise additional capital and could be forced to delay, further reduce or to explore other strategic options for certain of its development programs, or even terminate its operations; IN8bio’s ability to continue to operate as a going concern; the risk that IN8bio may not realize the intended benefits of its DeltEx platform and TCE program; availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of IN8bio’s product candidates; the uncertainty of regulatory approvals to conduct trials or to market products; IN8bio’s reliance on third parties, including licensors and clinical research organizations; and other important factors, any of which could cause IN8bio’s actual results to differ from those contained in the forward-looking statements, which are described in greater detail in the section entitled “Risk Factors” in IN8bio’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 7, 2026, as well as in other filings IN8bio may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and IN8bio expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Investors and Corporate Contact:
IN8bio, Inc.
Patrick McCall
646.933.5603
Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
IN8BIO, INC.
BALANCE SHEETS
(In thousands, except share and per share data)
|
|
June 30, |
|
|
|
|
||
|
|
2026 |
|
|
December 31, |
|
||
|
|
(unaudited) |
|
|
2025 |
|
||
Assets |
|
|
|
|
(Note 2) |
|
||
Current assets |
|
|
|
|
|
|
||
Cash |
|
$ |
17,956 |
|
|
$ |
27,092 |
|
Prepaid expenses and other current assets |
|
|
540 |
|
|
|
788 |
|
Total Current Assets |
|
|
18,496 |
|
|
|
27,880 |
|
Non-current assets |
|
|
|
|
|
|
||
Property and equipment, net |
|
|
1,600 |
|
|
|
1,858 |
|
Restricted cash |
|
|
176 |
|
|
|
220 |
|
Right-of-use assets - finance leases |
|
|
125 |
|
|
|
296 |
|
Right-of-use assets - operating leases |
|
|
1,246 |
|
|
|
1,882 |
|
Other non-current assets |
|
|
102 |
|
|
|
146 |
|
Total Non-Current Assets |
|
|
3,249 |
|
|
|
4,402 |
|
Total Assets |
|
$ |
21,745 |
|
|
$ |
32,282 |
|
Liabilities and Stockholders' Equity |
|
|
|
|
|
|
||
Liabilities |
|
|
|
|
|
|
||
Current liabilities |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
444 |
|
|
$ |
309 |
|
Accrued expenses and other current liabilities |
|
|
761 |
|
|
|
1,633 |
|
Short-term finance lease liability |
|
|
126 |
|
|
|
295 |
|
Short-term operating lease liability |
|
|
923 |
|
|
|
924 |
|
Total Current Liabilities |
|
|
2,254 |
|
|
|
3,161 |
|
Long-term operating lease liability |
|
|
1,128 |
|
|
|
1,563 |
|
Total Non-Current Liabilities |
|
|
1,128 |
|
|
|
1,563 |
|
Total Liabilities |
|
|
3,382 |
|
|
|
4,724 |
|
Stockholders' Equity |
|
|
|
|
|
|
||
Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; no shares issued and outstanding |
|
|
— |
|
|
|
— |
|
Common stock, par value $0.0001 per share; 490,000,000 shares authorized at June 30, 2026 and December 31, 2025; 9,853,121 and 9,766,132 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively |
|
|
10 |
|
|
|
10 |
|
Additional paid-in capital |
|
|
169,320 |
|
|
|
168,644 |
|
Accumulated deficit |
|
|
(150,967 |
) |
|
|
(141,096 |
) |
Total Stockholders' Equity |
|
|
18,363 |
|
|
|
27,558 |
|
Total Liabilities and Stockholders' Equity |
|
$ |
21,745 |
|
|
$ |
32,282 |
|
|
|
|
|
|
|
|
||
IN8BIO, INC.
STATEMENTS OF OPERATIONS
(In thousands, except share and per share data)
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
|
||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
$ |
2,493 |
|
|
$ |
2,487 |
|
|
$ |
5,106 |
|
|
$ |
5,459 |
|
|
General and administrative |
|
|
2,442 |
|
|
|
2,714 |
|
|
|
5,095 |
|
|
|
5,402 |
|
|
Total operating expenses |
|
|
4,935 |
|
|
|
5,201 |
|
|
|
10,201 |
|
|
|
10,861 |
|
|
Interest income |
|
|
154 |
|
|
|
107 |
|
|
|
330 |
|
|
|
217 |
|
|
Loss from operations |
|
|
(4,781 |
) |
|
|
(5,094 |
) |
|
|
(9,871 |
) |
|
|
(10,644 |
) |
|
Net loss |
|
$ |
(4,781 |
) |
|
$ |
(5,094 |
) |
|
$ |
(9,871 |
) |
|
$ |
(10,644 |
) |
|
Net loss per share – basic and diluted |
|
$ |
(0.25 |
) |
|
$ |
(1.24 |
) |
|
$ |
(0.51 |
) |
|
$ |
(3.65 |
) |
|
Weighted-average number of shares used in computing net loss per common share, basic and diluted |
|
|
19,467,091 |
|
|
|
4,119,153 |
|
|
|
19,468,087 |
|
|
|
2,920,157 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
# # #